The application of APR patented Immediate Release Technology to a formulation in granular powder of Potassium Diclofenac 50mg. resulted in a product with unique properties in the therapy of Migraine, demonstrated by specific Phase III Clinical trials, absolutely outstanding compared to other NSAID’s product for Migraine and equivalent to oral Triptan products.
APR Fastest for Migraine may be considered the election 1st line therapy in migraine attacks (also Severe) since:
While specific clinical studies demonstrated, already in 1999, the substantial equivalence of 50mg Potassium Diclofenac and 100mg Sumatriptan in Migraine treatments (cfr Drugs 1999 Jun; 57(6):991-1003 McNeely W, Goa KL), recent Phase III clinical studies made on APR fastest for Migraine demonstrated the greater superiority of this IRT based formulation towards other Potassium Diclofenac in the treatment of Migraine.A summary of these results:
The patent has been granted in the following countries: Europe, USA, Switzerland, Taiwan, South Africa, New Zealand, Australia and Poland. The Patent is still pending in the following countries: Argentina, Canada
In February 2003 APR entered an exclusive license agreement with Novartis Pharma AG in Basel for several countries:
APR Fastest for Migraine is already registered and ready for launch in: Germany, Sweden, Denmark, Norway, Finland, Ireland, Portugal, Ukraine, Brasil and certain other non European countries
APR Fastest for Migraine is available for registration and licensing in several other EU and non EU countries including:United Kingdom, France, Austria
Mr Paolo Galfetti
APR is a private, independent, integrated Healhcare Company focused on Delivering, Funding and Supporting Innovation in Healthcare.View profile
Clients in focus...